Investor Relations - Press Releases

Investor Alerts

Sep 12, 2019

Armata Pharmaceuticals Announces Development of New Synthetic Phage Candidate Targeting Pseudomonas aeruginosa

Initial clinical emphasis on difficult-to-treat respiratory infections in cystic fibrosis patients

Armata Pharmaceuticals, Inc. (NYSE American: ARMP) (the "Company" or "Armata"), a clinical-stage biotechnology company focused on precisely targeted bacteriophage therapeutics for...
Aug 14, 2019

Armata Pharmaceuticals Announces Second Quarter Results and Provides Corporate and Clinical Update

Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a clinical-stage biotechnology company focused on precisely targeted bacteriophage therapeutics for...
Aug 1, 2019

Armata Pharmaceuticals to Provide Corporate Update at the 39th Annual Canaccord Genuity Growth Conference

Armata Pharmaceuticals, Inc. (NYSE American: ARMP), a clinical-stage biotechnology company focused on precisely targeted bacteriophage therapeutics for antibiotic-resistant infections, today...
Jun 18, 2019

Armata Pharmaceuticals to Host Key Opinion Leader Meeting on Bacteriophage-Based Therapeutics on June 26 in New York

Armata Pharmaceuticals, Inc. (NYSE American: ARMP), a clinical-stage biotechnology company focused on precisely targeted bacteriophage therapeutics for antibiotic-resistant infections, today...
Jun 3, 2019

Armata Pharmaceuticals Strengthens Intellectual Property Portfolio with New Patent Allowances in Europe and Canada

Patent allowances cover various aspects of the Company's phage program and lead product candidate, AP-SA01

Armata Pharmaceuticals, Inc. (NYSE American: ARMP), a clinical-stage biotechnology company focused on precisely targeted bacteriophage therapeutics for antibiotic-resistant infections, today...

Show per page